COVID-19 Vaccine Technical Advisory Group (CV TAG)

The COVID-19 Vaccine Technical Advisory Group provides science advice and recommendations on the use of COVID-19 vaccinations.

Membership

  • Dr Ian Town (Chair) – Chief Science Advisor, Ministry of Health
  • Dr Danny de Lore – Paediatrician, Lakes DHB
  • Prof David Murdoch (Deputy Chair) – Dean and Head of Campus, University of Otago, Christchurch
  • Dr Elizabeth Wilson – S.M.O Paediatric Infectious Diseases, ADHB
  • Dr Helen Petousis-Harris – Associated Professor, University of Auckland
  • Prof Ian Frazer – Professor of Medicine, The University of Queensland
  • Assoc Prof James Ussher – Associate Professor, University of Otago and Science Director, Vaccine Alliance Aotearoa New Zealand (VAANZ)
  • Dr Nikki Moreland – Associated Professor, University of Auckland
  • Prof Nikki Turner – Medical Director, Immunisation Centre (IMAC), University of Auckland
  • Prof Peter McIntyre – Professor, University of Otago, Medical consultant, IMAC, and Professorial Fellow, NCIRS and University of Sydney, Australia
  • Dr Owen Sinclair, Te Rarawa – Paediatrician, Māori Health, Waitemata DHB
  • Dr Sean Hanna – General Practitioner and Chair, Immunisation Subcommittee PTAC
  • Prof Sue Crengle – General Practitioner and Professor, University of Otago
  • Assoc Prof Tony Walls – Associate Professor of Paediatrics, University of Otago and Paediatric Infectious Diseases Specialist

COVID-19 Vaccine Technical Advisory Group (CV-TAG) Memos

22 June 2022 - Second booster update: COVID-19 Vaccine Technical Advisory Group (CV TAG) recommendations (PDF, 347 KB) 

To provide the COVID-19 Vaccine Technical Advisory Group’s (CV TAG) advice on the science rationale, safety and peak body guidance on use of a second booster dose in:

  • individuals with underlying health conditions that are likely to increase the individual’s risk of adverse outcomes from COVID-19 and/or
  • those aged over 50 years and/or
  • extension of eligibility for a second booster dose to healthcare workers.

This updated document was re-issued on 26 July 2022 and provides clarification (particularly around use of a second booster dose in pregnant people) to ensure original intent is clear. Evidence provided and recommendations made on 22 June 2022 remain unchanged.

6 May 2022 - Use of Novavax (Nuvaxovid) COVID-19 vaccine as a heterologous booster: COVID-19 Vaccine Technical Advisory Group (CV TAG) recommendations (PDF, 275 KB)

To summarise the COVID-19 Vaccine Technical Advisory Group’s (CV TAG) advice about the use of Novavax COVID-19 vaccine(Nuvaxovid) as a heterologous booster.

30 March 2022 - Booster doses after myocarditis/pericarditis:COVID-19 Vaccine Technical Advisory Group (CV TAG) recommendations (PDF, 453 KB)

To summarise the COVID-19 Vaccine Technical Advisory Group’s (CV TAG) advice on the use of COVID-19 vaccines in those who have experienced vaccine-associated myocarditis and/or pericarditis after a second (or subsequent) dose.

22 March 2022 - COVID-19 Vaccine Technical Advisory Group (CV TAG) recommendations: Vaccination after infection with SARS-CoV-2 (PDF, 188 KB)

To summarise the COVID-19 Vaccine Technical Advisory Group’s(CV TAG) recommendations on COVID-19 vaccination after infection in circumstances when the recommended course of vaccination has not been completed.

22 March 2022 - Third primary dose of the paediatric Pfizer mRNA COVID-19 vaccine for immunocompromised 5–11-year-olds: COVID-19 Vaccine Technical Advisory Group (CV TAG) recommendations (PDF, 274 KB)

To summarise the COVID-19 Vaccine Technical Advisory Group’s (CV TAG) recommendations on the use of a third primary dose of the paediatric Pfizer mRNA COVID-19 vaccine in severely immunocompromised 5–11-year-olds.

21 February 2022 - The use of booster vaccinations in 12–17-year-olds: COVID-19 Vaccine Technical Advisory Group (CV TAG) recommendations (PDF, 320 KB)

To summarise the COVID-19 Vaccine Technical Advisory Group’s (CV TAG) recommendations on the use of COVID-19 booster vaccinations in 12–17-year-olds.

16 February 2022 - Use of the paediatric Pfizer COVID-19 vaccine  in 5-11 year-olds–second dose and dosing interval: COVID-19 Vaccine Technical Advisory Group (CV TAG) recommendations (PDF, 359 KB)

To outline the COVID-19 Vaccine Technical Advisory Group’s (CV TAG) advice about the administration o fa second dose of the paediatric Pfizer vaccine and the interval between the first and second doses of the COVID-19 vaccine for 5–11year-olds. This report also provides an update on international and local safety data.

10 February 2022 - Decision to use a primary course of the Novavax COVID-19 vaccine: COVID-19 Vaccine Technical Advisory Group (CV TAG) recommendations (PDF, 96 KB)

To summarise the COVID-19 Vaccine Technical Advisory Group’s (CV TAG) recommendations on the decision to use a primary course (two doses) of the Nuvaxovid COVID-19 Vaccine with Matrix-M Adjuvant (‘the Novavax vaccine’).

10 February 2022 - Decision to use the AstraZeneca COVID-19 vaccine as a booster for those aged 18 years and over 3 months after a primary vaccine course: COVID-19 Vaccine Technical Advisory Group (CV TAG) Recommendation (PDF, 158 KB)

To summarise the COVID-19 Vaccine Technical Advisory Group’s (CV TAG) recommendation on the decision to use the AstraZeneca COVID-19 vaccine (‘the AstraZeneca vaccine’) as a booster 3 months after a primary vaccination course for those aged 18 years and over.

1 February 2022 - COVID-19 booster vaccination interval for those aged 18 years and over in the context of Omicron: COVID-19 Vaccine Technical Advisory Group (CV TAG) Recommendation (PDF, 672 KB)

To summarise the COVID-19 Vaccine Technical Advisory Group’s (CV TAG) recommendations on the interval between COVID-19 primary course vaccinations and booster doses for those aged 18 years and over in the context of Omicron.

25 January 2022 - Update to recommendations on COVID-19 booster vaccinations for pregnant people and immunocompromised: COVID-19 Vaccine Technical Advisory Group (CV TAG) recommendations (PDF, 502 KB)

To summarise the COVID-19 Vaccine Technical Advisory Group’s (CV TAG) recommendations about COVID-19 booster vaccinations in pregnant and immunocompromised people.

17 December 2021 - Recommendation on COVID-19 vaccine booster dose interval update: COVID-19 Vaccine Technical Advisory Group (CV TAG) Recommendation (PDF, 959 KB)

To summarise the COVID-19 Vaccine Technical Advisory Group’s (CV TAG) recommendations about booster doses of the Pfizer vaccine.

15 December 2021 - Decision to use the Pfizer mRNA COVID-19 vaccine for children aged 5-11 years: COVID-19 Vaccine Technical Advisory Group (CV TAG) recommendations (PDF, 294 KB)

To summarise the CV TAG recommendations on the decision to use the paediatric formulation of the Pfizer mRNA COVID-19 vaccine (‘the Pfizer vaccine’) for children who are 5 to 11 years of age.

9 December 2021 - COVID-19 Vaccine Technical Advisory Group (CV TAG) position statement: Vaccination mandates in those under 18 years of age (PDF, 93 KB)

To state the COVID-19 Vaccine Technical Advisory Group’s (CV TAG) position on requiring two doses of Pfizer COVID-19 vaccine to fulfil vaccine mandates in those aged under 18 years.

17 November 2021 - Third Primary Pfizer mRNA COVID-19 vaccine dose in the immunocompromised: COVID-19 Vaccine Technical Advisory Group (CV TAG) Updated recommendations (PDF, 234 KB)

To summarise the COVID-19 Vaccine Technical Advisory Group’s (CV TAG) updated recommendations on the use of a third primary Pfizer mRNA COVID-19 vaccine dose in those who are severely immunocompromised.

10 November 2021 - Recommendations to provide a booster vaccination: COVID-19 Vaccine Technical Advisory Group (CV TAG) Recommendations (PDF, 192 KB)

To summarise the COVID-19 Vaccine Technical Advisory Group’s (CV TAG) recommendations about COVID-19 booster vaccinations.

5 November 2021 - New Zealand definition of fully vaccinated for use inside the New Zealand border: COVID-19 Vaccine Technical Advisory Group (CV TAG) Recommendation (PDF, 235 KB)

To summarise the COVID-19 Vaccine Technical Advisory Group’s (CV TAG) recommendations on the definition of fully vaccinated for use in settings inside the New Zealand border.

3 November 2021 - Temporary Medical Exemptions for the COVID-19 Vaccine: COVID-19 Vaccine Technical Advisory Group (CV TAG) recommendations (PDF, 148 KB)

To outline the COVID-19 Vaccine Technical Advisory Group’s (CV TAG) recommendations on the clinical criteria for medical exemptions to the first or second dose of the Pfizer COVID-19 vaccine.

27 October 2021 - Decision to use the AstraZeneca COVID-19 vaccine: COVID-19 Vaccine Technical Advisory Group (CV TAG) recommendations (PDF, 171 KB)

To summarise the COVID-19 Vaccine Technical Advisory Group’s (CV TAG) recommendations on the decision to use the AstraZeneca COVID-19 vaccine (‘the AstraZeneca vaccine’).

1 October 2021 - COVID-19 vaccines for arrivals to Aotearoa New Zealand: COVID-19 Vaccine Technical Advisory Group (CV TAG) Recommendations (PDF, 137 KB)

This memo summarises the COVID-19 Vaccine Technical Advisory Group’s (CV TAG) recommendations on COVID-19 vaccination requirements for people arriving to the country under the Recognised Seasonal Employer (RSE) scheme. These recommendations are made as a part of the next step in the phased introduction of vaccination requirements at the border.

29 September 2021 - COVID-19 vaccines for arrivals to Aotearoa New Zealand: COVID-19 Vaccine Technical Advisory Group (CV TAG) Recommendations (PDF, 884 KB)

This memo summarises the COVID-19 Vaccine Technical Advisory Group’s (CV TAG) recommendations on COVID-19 vaccination requirements for people arriving to the country and entering managed isolation and quarantine (MIQ) for 14 days. These recommendations are made as a part of a first step in the phased introduction of vaccination requirements at the border.

21 September 2021 - Additional Pfizer mRNA COVID-19 vaccine dose in the immunocompromised: COVID-19 Vaccine Technical Advisory Group (CV TAG) recommendations (PDF, 286 KB)

To summarise the COVID-19 Vaccine Technical Advisory Group’s (CV TAG) recommendations on the use of an additional Pfizer mRNA COVID-19 vaccine dose in those who are immunocompromised.

6 September 2021 - COVID-19 vaccines and vaccinations recognise at the border for border workers: COVID-19 Vaccine Technical Advisory Group (CV TAG) Recommendation (PDF, 217 KB)

To summarise the COVID-19 Vaccine Technical Advisory Group’s (CV TAG) recommendations on COVID-19 vaccines that Aotearoa New Zealand recognises for those working at the international border (‘the Border’), including advice on the criteria for deciding which vaccines should be recognised at the Border, and how to approach incomplete vaccination with recognised COVID-19 vaccines and vaccination with non-recognised COVID-19 vaccines among ‘Border Workers’.

6 September 2021 - Guidance for the potential use of an extension/third dose in the context of a missed vaccination incident: COVID-19 Vaccine Technical Advisory Group (CV TAG) Recommendation (PDF, 167 KB)

To provide guidance for clinical decision-making around offering an extension/third dose in the context of a missed vaccination incident, including specific advice about those who are immunocompromised.

27 August 2021 - Coadministration of the COVID-19 vaccine with other vaccines, including the MMR and influenza vaccines: COVID-19 Vaccine Technical Advisory Group (CV TAG) recommendations (PDF, 139 KB)

To summarise the COVID-19 Vaccine Technical Advisory Group’s (CV TAG) recommendations for coadministration of the Pfizer COVID-19 vaccine with the MMR, influenza, and other vaccines.

20 August 2021 - The use of COVID-19 vaccines during an outbreak: COVID-19 Vaccine Technical Advisory Group (CV TAG) recommendations for prioritisation of first doses nationwide (PDF, 123 KB)

To summarise the COVID-19 Vaccine Technical Advisory Group’s recommendations on the use of COVID-19 vaccines during an outbreak, endorsing the prioritisation of vaccination capacity nationwide to allow the maximum number of people to receive at least a single dose of the Pfizer COVID-19 vaccine.

4 August 2021 - Priority groups for vaccination among 12- to 15-year-olds: COVID-19 Vaccine Technical Advisory Group (CV TAG) recommendations on the use of the Pfizer vaccine (PDF, 128 KB)

To summarise the COVID-19 Vaccine Technical Advisory Group’s (CV TAG) recommendations on priority groups for Pfizer mRNA COVID-19 vaccination among 12- to 15-year-olds.

21 July 2021 - Myocarditis following vaccination: COVID-19 Vaccine Technical Advisory Group (CV TAG) recommendations on the use of the Pfizer vaccine (PDF, 193 KB)

To summarise the COVID-19 Vaccine Technical Advisory Group’s (CV TAG) recommendations on the use of Pfizer mRNA COVID-19 vaccine in the context of the risk of myocarditis and/or pericarditis following vaccination.

12 July 2021 - Decision to use the Janssen COVID-19 vaccine: COVID-19 Vaccine Technical Advisory Group (CV TAG) Recommendation (PDF, 79 KB)

To summarise the COVID-19 Vaccine Technical Advisory Group’s (CV TAG) recommendations on the decision to use the Janssen COVID-19 vaccine.

24 June 2021 - Decision to use the Pfizer mRNA COVID-19 vaccine for children aged 12 -15 years: COVID-19 Vaccine Technical Advisory Group (CV TAG) Recommendation (PDF, 87 KB)

To summarise the COVID-19 Vaccine Technical Advisory Group’s (CV TAG) recommendations on the decision to use the Pfizer mRNA COVID-19 vaccine for children aged 12-15 years.

27 May 2021 - Pfizer COVID-19 vaccine in pregnancy: COVID-19 Vaccine Technical Advisory Group (CV TAG) Recommendation (PDF, 79 KB)

To outline the COVID-19 Vaccine Technical Advisory Group’s revised recommendations for use of the Pfizer COVID-19 vaccine in pregnancy.

27 May 2021 -  Decision to use the Pfizer mRNA COVID-19 vaccine for group three and general population: COVID-19 Vaccine Technical Advisory Group (CV TAG) Recommendation (PDF, 76 KB)

To outline the COVID-19 Vaccine Technical Advisory Group’s recommendations on the decision to use the Pfizer mRNA COVID-19 vaccine for group three at scale and the general population in New Zealand

12 May 2021 - The use of COVID-19 vaccines during an outbreak: COVID-19 Vaccine Technical Advisory Group (CV TAG) Recommendation (PDF, 135 KB)

To outline the COVID-19 Vaccine Technical Advisory Group’s recommendations for the targeted use of COVID-19 vaccines during an outbreak.

20 April 2021 - Guidance for testing in recently vaccinated populations: COVID-19 Vaccine Technical Advisory Group (CV TAG) Advice (PDF, 204 KB)

To outline the COVID-19 Vaccine Technical Advisory Group’s (CV TAG) advice for new guidance for testing in the days, weeks and months following a person’s vaccination.

13 April 2021 - Pfizer dosing regimen for those arriving in New Zealand with a prior vaccine History: COVID-19 Vaccine Technical Advisory Group (CV TAG) Recommendation (PDF, 198 KB)

To outline the COVID-19 Vaccine Technical Advisory Group's recommendation following a request for advice on the Pfizer dosing regimen for those arriving in New Zealand with a prior vaccine history.

25 March 2021 - COVID-19 vaccines in children younger than 16 years: COVID-19 Vaccine Technical Advisory Group (CV TAG) Recommendation (PDF, 86 KB)

To outline the COVID-19 Vaccine Technical Advisory Group's recommendations for the use of COVID-19 vaccines in children younger than 16 years.

17 March 2021 - Use of mRNA Pfizer/BioNTech COVID-19 vaccine with respect to patients receiving immune checkpoint inhibitor (ICI) therapy: COVID-19 Vaccine Technical Advisory Group (CV TAG) Recommendation (PDF, 230 KB)

To update the COVID-19 Vaccine Technical Advisory Group's recommendations on the use of the Pfizer/BioNTech COVID-19 vaccine for individuals receiving immune checkpoint inhibitor (ICI) therapy.

17 March 2021 - Comorbidities associated with poor COVID-19 outcomes for vaccine sequencing considerations: COVID-19 Vaccine Technical Advisory Group (CV TAG) Recommendation (PDF, 264 KB)

To outline the COVID-19 Vaccine Technical Advisory Group's recommendation following a request for opinion regarding the definitions/ thresholds to be used for vaccinating individuals with hypertension and obesity

8 March 2021 - Reduction of 30-minute observation time for Pfizer COVID-19 Vaccine: COVID-19 Vaccine Technical Advisory Group (CV TAG) Recommendation (PDF, 88 KB)

To outline the COVID-19 Vaccine Technical Advisory Group’s recommendation following a request to reconsider the current requirement for individuals to be observed for 30 minutes after receiving the Pfizer COVID-19 vaccine.

5 February 2021 - Decision to use the Pfizer mRNA COVID-19 vaccine: COVID-19 Vaccine Technical Advisory Group (CV TAG) Recommendation (PDF, 115 KB)

To outline the COVID-19 Vaccine Technical Advisory Group’s (CV TAG) recommendations on for whom the Pfizer mRNA COVID-19 vaccine is appropriate.

Back to top